Dengue more common than malaria in travelers returning from Asia

The risk of dengue infection can be reduced by all-day protection against mosquito bites, for example with repellents. Vaccines are also in development. In a 4.5-year placebo-controlled phase III study (TIDES: Tetravalent Immunization against Dengue Efficacy Study) in seropositive and seronegative subjects, two doses of Takeda’s tetravalent vaccine candidate prevented 61 percent of symptomatic infections and 84 percent of hospitalizations. The TAK-003 vaccine is based on a live, attenuated serotype 2 dengue virus.

See also  Doctors discover a shocking thing in the colon of an American man



Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Social Media

Most Popular

On Key

Related Posts

DER SPIEGEL – App update

Please update your application. We have renewed our DER SPIEGEL app. Unfortunately, older app versions no longer work for technical reasons. Please update your app